Investment and experience for growth.

Cohda Wireless is a leading supplier of Connected Autonomous Vehicle solutions that enable vehicles to connect with other vehicles and intelligent infrastructure in highway, smart city and mining environments. Its patented accurate-positioning technology helps vehicles, people and objects interact safely and seamlessly in real time. M-Group has participated in three investment rounds and was instrumental in bringing Cisco and NXP onboard as Cohda shareholders.

Inlink pioneered elevator-based content delivery systems and built Australia’s largest CBD digital out-of-home media network, with some 2,800 screens by 2015. The company was sold to oOh!media in 2015. Before the sale, part of Inlink’s software team was spun out into Xperior, a tenant portal business for commercial property owners and managers; M-Group was a foundation shareholder and the business was sold in 2018.

Established in 2018 by the former Inlink investor cohort and board, iPro combines cloud technology and best practice to help businesses manage risk and compliance. Its platform provides smart assessments, actionable insights and process automation across areas such as ESG, gender balance and modern slavery. M-Group is represented on the board.

McMillan Shakespeare is an ASX-listed provider of salary packaging, novated leasing, consumer and fleet financing and management services across Australia, New Zealand and the UK. M-Group coordinated the leveraged management buy-out, provided significant investment and managed the company’s ASX IPO.

M-Group is the majority and cornerstone private investor in this fund, which was awarded one of four AusIndustry Pre-Seed Fund licences by the Federal Government. Co-investors include CSIRO and nine Australian universities.

Cellestis developed medical diagnostic technology, including the QuantiFERON-TB product range that became a global standard for diagnosing latent tuberculosis. An M-Group affiliate was a key establishment partner, provided capital and managed the company’s ASX IPO. Cellestis was acquired by QIAGEN in 2011.

Ascend is an early-stage biopharmaceutical company developing treatments for nodular basal cell carcinomas, especially where conventional therapies are difficult to apply. Formed from the merger of 4G Vaccines and IgAvax, its original research and development activities commenced in 2006 with SciVentures funding.

Glutagen is a Melbourne biopharmaceutical company focused on products that support people who experience difficulty digesting gluten. Its first product, GluteGuard®, was built on decades of clinical research led by Professor Hugh Cornell AO at RMIT University. M-Group funding supported its development, clinical trials and market launch.

One of Australia’s first SaaS providers, Acendre evolved from recruitment and talent acquisition into a fully integrated talent management platform. Its cloud-based solutions have been used by major enterprises and US federal agencies. M-Group was involved from 2003 and exited when the company was acquired by Strattam Capital.

Formerly Azure Healthcare, Austco is an international provider of healthcare communications and clinical workflow management solutions. Headquartered in Australia and listed on the ASX, it supports more than 6,000 healthcare facilities through its global network. An M-Group affiliate is a substantial shareholder.

Avipep is a Melbourne company developing Avibodies, the key binding domains of antibodies, as a platform for targeting cells in the body. Its focus includes antibody-drug conjugates for cancer treatment. M-Group investment has assisted development and clinical trials.

An M-Group affiliate is the majority owner of APVC Finance, which provides financial services to members of the Accor Group’s Vacation Club.